Abstract: Treating Sonic Hedgehog-Associated Medulloblastoma comprises inhibiting the synthesis or biologic activity of leukotrienes that drive Nestin expression in cancerous or precancerous granule neuron precursors and that further drive growth and proliferation of medulloblastoma cells through Nestin-mediated aberrant Sonic Hedgehog signaling.

Abstract: A method and system for scheduling, tracking, recording, and monitoring of patients' usage of an infusion room, along with various tools to analyze the infusion room activity, to thereby improve usage of the infusion room, and improve patient satisfaction relating to their infusion room experience, is disclosed. The inventive methods and systems use real-time computer processors, software, and distributed sensors to monitor, record, analyze, and graphically display relevant infusion room chair status, patient status, and patient medical condition while in the infusion room. In preferred embodiments, the inventive methods and systems provide real-time input capability for medical personnel, and real-time automatic data output for use by or to prompt medical personnel. The inventive methods and systems are capable of recording activity of the infusion room to permit later analysis, modeling, and simulation to allow for improvements in infusion room efficiencies and patient satisfaction.

Abstract: Systems and methods for diagnosing or characterizing a predisposition to colon cancer are provided. Cell nuclei may be evaluated for the presence or quantity of gamma-H2AX foci. Nucleic acids may be evaluated for the presence, type, or quantity of genomic instability or surrogates of dsDNA breaks such as ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), and Tumor suppressor p53-binding protein 1 (53BP1) in gamma-H2AX foci. Nucleic acids comprising a germline nucleic acid sequence of the ERCC6, WRN, TERT, and FAAP100 genes may be sequenced or probed to determine if the nucleic acid sequence includes one or more alterations that cause genomic instability, dsDNA breaks, or gamma-H2AX foci or otherwise predispose a subject to develop colon cancer.

Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.